Literature DB >> 6187879

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

C Uyttenhove, J Maryanski, T Boon.   

Abstract

Even though mastocytoma P815 often undergoes a nearly complete rejection in syngeneic mice, the tumor cells almost always escape to form progressive tumors. We found that this was not due to the establishment of an immunosuppressed state because genetically marked P815 cells, that were injected in mice where tumor escape was occurring, were readily rejected. An analysis of escaping tumor cell populations with anti-P815 cytolytic T lymphocyte (CTL) clones showed the presence of stable resistant variants. Using antigen-loss variants found in escaping populations or selected in vitro with CTL clones, we were able to define four different tumor-associated antigenic specificities, each recognized by a specific CTL clone. One of these specificities was absent from all escaping tumor cells and another had been lost by some of them.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187879      PMCID: PMC2186952          DOI: 10.1084/jem.157.3.1040

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

2.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.

Authors:  C Uyttenhove; J Van Snick; T Boon
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

3.  Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.

Authors:  W E Biddison; J C Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

4.  In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

5.  Characterization of suppressor cells in mice bearing syngeneic mastocytoma.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

6.  The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice.

Authors:  K J Weinhold; L T Goldstein; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

7.  The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.

Authors:  K J Weinhold; D A Miller; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

8.  Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.

Authors:  R N Germain; M E Dorf; B Benacerraf
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  55 in total

1.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

2.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  Characterization of gene expression profiles of T cells during anti-tumor response.

Authors:  Christian Stremmel; Renate Siebenhaar; Roland Croner; Bertram Reingruber; Anthony J Slavin; Werner Hohenberger
Journal:  Int J Colorectal Dis       Date:  2005-04-06       Impact factor: 2.571

Review 4.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 5.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

6.  Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.

Authors:  Herbert W Kavunja; Shuyao Lang; Suttipun Sungsuwan; Zhaojun Yin; Xuefei Huang
Journal:  Cancer Immunol Immunother       Date:  2016-12-23       Impact factor: 6.968

7.  Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

Authors:  A Knuth; T Wölfel; E Klehmann; T Boon; K H Meyer zum Büschenfelde
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 8.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

9.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis.

Authors:  V A Kuznetsov; I A Makalkin; M A Taylor; A S Perelson
Journal:  Bull Math Biol       Date:  1994-03       Impact factor: 1.758

10.  Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis.

Authors:  Chi-Shan Li; Chong Chen; Pan Zheng; Yang Liu
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.